RecruitingNCT06280755

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study

Sponsor

icometrix

Enrollment

7,000 participants

Start Date

Mar 1, 2024

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis Clinically Isolated Syndrome NMO Spectrum Disorder Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Radiologically Isolated Syndrome

Summary

The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS.
Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)/Ethical Committee (EC) approval in accordance with national and local subject privacy regulations.

Exclusion Criteria2

Patients under 18 years of age will be excluded.
Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.

Locations(3)

General University Hospital Prague

Prague, Praha 2, Czechia

Katholisches Klinikum Bochum - St. Joseph-Hospital

Bochum, Bochum, Germany

ERC Charité - Universitätsmedizin Berlin

Berlin, State of Berlin, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06280755

Related Trials

From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

NCT048734921 location

Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment

NCT067824641 location

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT074776392 locations

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

NCT0381634552 locations

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT072071481 location